



Australian Government
Department of Health
 Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	324631	NUTRA-LIFE ESTER-C + PROBIOTICS
ARTG entry for	Medicine Listed	
Sponsor	Vitaco Health Australia Pty Ltd	
Postal Address	PO Box 399, NORTH RYDE BC, NSW, 1670 Australia	
ARTG Start Date	10/10/2019	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . NUTRA-LIFE ESTER-C + PROBIOTICS

Product Type	Effective Date
Single Medicine Product	10/10/2019

Permitted Indications

- Antioxidant/Reduce free radicals formed in the body
- Helps reduce/decrease free radical damage to body cells
- Maintain/support collagen formation
- Maintain/support general health and wellbeing
- Maintain/support connective tissue health
- Aid/assist/helps connective tissue production/formation
- Maintain/support blood capillary health
- Maintain/support blood vessel health
- Maintain/support immune system health
- Maintain/support healthy immune system function
- Maintain/support absorption of dietary (state vitamin/mineral/nutrient)
- Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
- Aid/assist/helps synthesis of neurotransmitters
- Maintain/support nervous system health
- Maintain/support nervous system function
- Decrease/reduce/relieve common cold duration
- Decrease/reduce/relieve the severity of common cold symptoms
- Maintain/support skin health
- Maintain/support wound healing

Public Summary



Australian Government
Department of Health
 Therapeutic Goods Administration

Indication Requirements

Product presentation must not imply or refer to serious forms of respiratory disorders/diseases, such as: asthma, pneumonia, COAD, COPD, influenza.
 Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).
 Label statement: If symptoms persist, talk to your health professional.
 Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.
 Label statement: Adults only, OR Not to be used in children under 2 years of age without medical advice (or words to that effect).
 Product presentation must not imply or refer to serious immunological diseases.
 Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

(If medicine contains one sugar) contains [insert name of sugar] OR (If medicine contains two or more sugars) Contains sugars [or words to that effect].
 Bacillus coagulans may affect the way some medicines work, including immunosuppressants. Consult your health professional before taking with other medicines (or words to that effect)
 Not suitable for children.

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

1 . Formulation 1

Dosage Form	Tablet, chewable
Route of Administration	Oral

Visual Identification

Active Ingredients

Bacillus coagulans	500 million CFU
calcium ascorbate dihydrate	319.2 mg
Equivalent: ascorbic acid	250 mg
calcium carbonate	3.66 mg
calcium L-threonate	4.02 mg
Equivalent: calcium	.53 mg
Echinacea purpurea herb top flowering Juice concentrate	11.12 mg
Equivalent: Echinacea purpurea (Fresh)	500 mg
sodium ascorbate	284.1 mg
Equivalent: ascorbic acid	250 mg

Other Ingredients (Excipients)

ammonium glycyrrhizinate
 citric acid
 Flavour
 fructose
 glucose monohydrate
 magnesium stearate
 maize starch
 maltodextrin
 microcrystalline cellulose
 silicon dioxide



Australian Government

Department of Health
Therapeutic Goods Administration

Steviol glycosides

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary